Adding immunotherapy to first|line treatment of advanced and ...

Adding immunotherapy to first-line treatment of advanced ... - PubMed

The incorporation of immunotherapy into the initial treatment for advanced and metastatic endometrial cancer brings about a substantial ...

Adding immunotherapy to first-line treatment of advanced and ...

Immunotherapy added to chemotherapy improves disease-free and overall survival in advanced and metastatic endometrial cancer.

Adding immunotherapy to first-line treatment of advanced and ...

A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy.

Pembrolizumab for the treatment of PD-L1 positive advanced or ...

Platinum-based chemotherapy remains the preferred first-line treatment for most patients with advanced or metastatic non-small cell lung cancer (NSCLC) without ...

Adding immunotherapy to first-line treatment of advanced and ...

CONCLUSIONS: The incorporation of immunotherapy into the initial treatment for advanced and metastatic endometrial cancer brings about a substantial improvement ...

Expanded Role for Immunotherapy to Treat Endometrial Cancer - NCI

Adding immunotherapy to chemotherapy substantially increases how long people with advanced endometrial cancer live without their cancer ...

Immunotherapy in the First‐Line Treatment of Advanced ...

The available evidence demonstrates that the addition of immunotherapy to chemotherapy as a first-line treatment in the of advanced NPC ...

First-Line Dual Immunotherapy, a Treatment ... - ASCO Publications

First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non–Small-Cell Lung Cancer: Are We Ready to Use It? Authors: Dipesh ...

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

These data suggest that the incorporation of immunotherapy into the first-line treatment of patients with advanced or recurrent endometrial ...

Effect of Adding Chemotherapy to First-Line Immunotherapy in ...

Currently, FDA-approved options for the first-line treatment of PD-L1–high advanced NSCLC include immunotherapy with or without chemotherapy and with or without ...

Immunotherapy for the First-Line Treatment of Patients with ...

At this time, chemotherapy remains the preferred therapy for the patients with EGFR/ALK-positive NSCLC who have exhausted their TKI options. When to add PD-1/PD ...

Comparison between the first-line and second-line immunotherapy ...

Single immunotherapy drug treatment was proved to be essential in second-line immunotherapy as well, including pembrolizumab, nivolumab, atezolizumab, and ...

anti-PD-1 or anti-PD-L1? | Journal for ImmunoTherapy of Cancer

Recent randomized phase III trials (KEYNOTE-407 and IMpower131) reported that adding anti-programmed death (ligand) 1 (anti-PD-(L)1) antibodies in combination ...

SC14.01 Immunotherapy in the First-Line Setting of Advanced NSCLC

Immunotherapies have been found to be better tolerated than chemotherapy and have the potential for long-term survival, thus could benefit patients as first- ...

'Remarkable' Immunotherapy Trial Changes Advanced Lung Cancer ...

In the first large, randomized trial to look at immunotherapy as a first-line cancer treatment, researchers found that adding the immunotherapy ...

Is Immunotherapy the Only Treatment Some People Need? - NCI

Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment ... Results from several clinical trials suggest that, ...

First-line treatment for patients with advanced non-small cell lung ...

In conclusion, the addition of chemotherapy to pembrolizumab as first-line treatment further improves the outcomes of patients with advanced NSCLC and a PD-L1 ...

Association Between Duration of Immunotherapy and Overall ...

Patients in key pivotal studies informing the use of first-line immunotherapy use were treated with ICI therapy for up to 2 years (maximum ...

First-line immunotherapy in non-small cell lung cancer patients with ...

Treatment strategies involving immunotherapy have revolutionized the approach to advanced NSCLC in the first-line setting. Whereas the benefit observed in ...

Immunotherapy: From Advanced NSCLC to Early Stages ... - Frontiers

Then, first-line pembrolizumab monotherapy demonstrated its superiority over platinum-doublet in high PD-L1 NSCLC. The addition of pembrolizumab ...